Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).

@article{Jacob2012TiclopidineCA,
  title={Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).},
  author={Sony Jacob and Brianne L Dunn and Zaina P. Qureshi and Nicholas Bandarenko and Hau C. Kwaan and Dilip K. Pandey and June M Mckoy and Sara E. Barnato and Jeffrey L Winters and John Cursio and Ivy Weiss and Thomas J. Raife and Patricia M Carey and Ravindra Sarode and Joseph E Kiss and Constance Danielson and Thomas L Ortel and W. Clark and G. Rock and Masanori Matsumoto and Yoshihiro Fujimura and X Long Zheng and Hao Chen and Erwei Song and John Michael Armstrong and Dennis W. Raisch and Charles L Bennett},
  journal={Seminars in thrombosis and hemostasis},
  year={2012},
  volume={38 8},
  pages={845-53}
}
Thienopyridine-derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the most common drugs implicated in this syndrome. We reviewed 20 years of information on clinical, epidemiologic, and laboratory findings for thienopyridine-associated TTP. Four, 11, and 11 cases of thienopyridine-associated TTP were reported in the first year of marketing of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Drug-induced glomerular disease: direct cellular injury.

Clinical journal of the American Society of Nephrology : CJASN • 2015
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…